ProLynx announces initiation of the Phase II Topology clinical trial of its DNA-damaging agent PLX038 in triple-negative breast cancer at the Institut Curie
March 25, 2024 09:00 ET
|
ProLynx Inc.
SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. announced that the first patient was included in TOPOLOGY by investigator Dr. Delphine Loirat, with a Phase II clinical trial...
TROP2 Targeted Cancer Therapy Market Clinical Trials Companies Insight
March 20, 2023 02:55 ET
|
KuicK Research
Delhi, March 20, 2023 (GLOBE NEWSWIRE) -- Global TROP2 Antibody Market, Drug Sales & Clinical Trials Outlook 2028 Report Highlights: Global & Regional TROP2 Antibody Market Sales...
Multimedia Update: FDA Grants Accelerated Approval for Immunomedics’ Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer
April 23, 2020 08:00 ET
|
Immunomedics, Inc.
First FDA-approved antibody-drug conjugate that targets the Trop-2 antigen Trodelvy is the first antibody-drug conjugate approved by FDA specifically for the treatment of relapsed or refractory...